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Table 1. Primary Outcome
Table 2. Baseline Characteristics
Interventions:
• Comparison of pre- and post-survey responses following 
provider education sessions for the primary objective




• PMG primary care providers in Southern Oregon 
clinics
• Providers who choose to complete pre- and post-
surveys
• Patients:





• Asthma/COPD and asthma diagnoses
• Elevated IgE levels (>0.35 kIU/L) if obtained
Primary Outcome:
• There was statistically significant improvement seen after 
provider education for classification and initial treatment 
of COPD management as determined by pre- and post-
surveys.
• Other findings from provider surveys include: 
• Cost of inhalers was reported to be a barrier in COPD 
management 75-90% of the time. 
• Other overarching barriers identified include patient 
adherence, smoking cessation, formulary changes, 
and time and availability with the patient. 
Limitations:
• Reduced post-survey responses submitted after each 
provider education session. Pre-survey and post-survey 
answers were unable to be matched for analysis.
Secondary Outcome:
• All CAT/mMRC score reporting were conducted by 
pulmonology specialty and no change in reporting was 
seen in primary care clinics. 
• There was a change in baseline reporting of PFTs between 
January 2021 and March 2021 in primary care clinics. Two 
baseline PFTs were obtained in February 2021 post-
provider education. 
Limitations:
• Chart review only captured patients who presented to 
clinic for COPD in the months of January 2021 and March 
2021. Potential to have missed other patients with 
baseline PFT and/or mMRC/CAT score reporting.
• Percent appropriateness of inhaler therapy depended on 
CAT/mMRC score reporting. 
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To evaluate the efficacy of provider education on adherence to 
guideline-directed therapy in outpatient chronic obstructive 
pulmonary disease (COPD) management in South Oregon PMG 
clinics.
• Pharmacist-led provider education positively impacted 
COPD management as determined by pre- and post-
surveys
• Barriers identified for optimized COPD therapy fall under 
the scope for management by clinical pharmacy
• Further workflows to improve obtaining baseline PFTs and 
symptom reporting in primary care settings is needed
Background
• COPD is the third most common cause of death in the US
• The CDC reports costs attributable to COPD in 2010 were 
$32.1 billion – projected to have increased to $49 billion 
by 2020
• Direct healthcare costs include detection, prevention, 
physician office visits, hospitalizations, home care, and 
medications – hospitalizations accounting for about 45-
50% of these direct costs
• Clinical burden of uncontrolled COPD has been shown to 
impact quality of life, health status, daily activities, 
physical activity, sleep, comorbid anxiety and 
depression, and disease progression
• Data indicates a direct relationship between severity of 
COPD and overall cost of care. Studies have also shown 
that adherence to guideline-directed therapy for COPD 
decreases trends in cough and shortness of breath, 
exacerbations, emergency department visits, and 
hospitalizations
• PMG Clinical Pharmacists have shown positive outcomes 
in collaborative management of chronic disease states 
such as diabetes, hypertension, and cardiovascular risk 
reduction, making pharmacists well positioned to 
provide education on guideline adherence 
Methodology
• Primary Outcome
• Change in provider adherence to guideline-directed 
therapy in COPD management after provider 
education as determined by pre- and post-surveys
• Secondary Outcome
• Change in percentage of patients where a 
CAT/mMRC score was reported before and after 
survey intervention
• Baseline reporting of pulmonary function tests 
(PFTs)
• Change in percent appropriateness of inhaler 
therapy between February 2021 and March 2021 




Figure 1. Cost of Inhalers as a Barrier
Next Steps
• Propose to implement mMRC/CAT questionaries by clinic 
team prior to PCP visits
• Workflow for consults/referrals to clinical pharmacy in 
those whose COPD is not well controlled






Q1 Knowledge 6 9 0.0914
Q2 Classifying 18 19 0.0346
Q3 Classifying 8 14 0.0090
Q4 Initial Treatment 6 14 0.0019














Baseline reporting PFTs – n (%) 14 (63.6) 13 (76.5)*
Change in percent of CAT/mMRC scores 
reported – n (%)
3 (13.6)** 1 (0.06)**
Change in percent appropriateness of inhaler 
therapy – n (%)
3 (13.6) 1 (0.06)







Gender – male, no. (%) 18 (81.8) 11 (64.7)
Duration of COPD – yr 5.6 4.06
Pack year history >20 yrs, no. 14 7
Current smoker – no. (%) 8 (36.4) 5 (29.4)
Followed by pulmonology, no. (%) 2 (9.0) 2 (11.7)
Post-bronchodilator FEV1 – liters 1.95 2.0
Post-bronchodilator ratio of FEV1 to FVC 
– %
57.7 69.9






















Figure 2. Other Barriers
Chart Review Results
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